Key Takeaways
- Penn Engineers have enhanced lipid nanoparticles (LNPs) to target specific cells in the brain, offering potential treatments for neurological diseases.
- The modified LNPs effectively cross the blood-brain barrier and deliver mRNA to neurons and endothelial cells.
- This advancement could lead to more precise and less invasive therapies for conditions like Alzheimer’s and Parkinson’s.
Innovative Advances in Targeted Drug Delivery
Researchers at the University of Pennsylvania have successfully modified lipid nanoparticles (LNPs), the same technology utilized in COVID-19 mRNA vaccines, to specifically target neurons and other brain cells. This breakthrough could pave the way for next-generation therapies aimed at neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases.
In a recent publication in Nano Letters, the team described how peptides — short chains of amino acids — can enable LNPs to deliver mRNA directly to the endothelial cells lining blood vessels in the brain, as well as to neurons. This targeted delivery is crucial because effective treatments for neurodegenerative diseases rely on ensuring that mRNA reaches the correct cellular destination.
The researchers previously demonstrated that LNPs could cross the blood-brain barrier (BBB) to deliver mRNA but did not have the ability to direct which brain cells the LNPs would affect. Michael J. Mitchell, an Associate Professor in Bioengineering and the paper’s senior author, explained the significance of this work by likening it to the capability of sending a package to a specific destination rather than letting it land randomly.
The BBB serves as a protective barrier that typically prevents large molecules, including many pharmaceuticals and mRNA, from entering the brain. However, certain formulations of LNPs, which are partially made up of fat and similar compounds found in cooking oils, can penetrate this barrier.
In attempts to target specific cells, most prior research relied on attaching antibodies to LNPs. However, the large size of antibodies can hinder their ability to traverse the BBB. In contrast, peptides, which are smaller and cheaper to produce, provide a more stable and effective means of targeting specific cells in the brain. This methodology emerged from Emily Han’s research on rabies and how its virus crosses the BBB.
To ensure that peptides adhered effectively to LNPs, the team devised new quantification methods. Following this, they tested the peptide-functionalized LNPs (pLNPs) in animal models to verify they reached the intended targets within the complex structure of the brain.
The next phase of the research will focus on determining how many neurons need to be targeted with pLNPs to significantly alleviate symptoms of neurological conditions. This question is crucial in fine-tuning delivery strategies and moving closer to the development of effective therapies for diseases such as Alzheimer’s and Parkinson’s.
This innovative work represents a significant advancement in mRNA-based medicine, suggesting a future where targeted treatments could revolutionize the management of serious neurological diseases.
The content above is a summary. For more details, see the source article.